

REFERENCES TO T-CELL VACCINATIONS

1. Cookson, W. Genetics and genomics of asthma and allergic diseases. *Immunol. Rev.* **190**, 195–206 (2002). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
2. Merriman, T.R. & Todd, J.A. Genetics of autoimmune disease. *Curr. Opin. Immunol.* **7**, 786–792 (1995). | [Article](#) | [PubMed](#) | [ChemPort](#) |
3. Sawcer, S. *et al.* A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. *Nat. Genet.* **13**, 464–468 (1996). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
4. Bali, D. *et al.* Genetic analysis of multiplex rheumatoid arthritis families. *Genes Immun.* **1**, 28–36 (1999). | [Article](#) | [PubMed](#) | [ChemPort](#) |
5. Strachan, D.P. Hay fever, hygiene, and household size. *Br. Med. J.* **299**, 1259–1260 (1989). | [ISI](#) | [ChemPort](#) |
6. Gale, E.A. A missing link in the hygiene hypothesis? *Diabetologia* **45**, 588–594 (2002). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
7. Heaton, T. *et al.* An immunoepidemiological approach to asthma: identification of *in vitro* T-cell response patterns associated with different wheezing phenotypes in children. *Lancet* **365**, 142–149 (2005). | [Article](#) | [PubMed](#) | [ChemPort](#) |
8. Hansen, G., Berry, G., DeKruyff, R.H. & Umetsu, D. T. Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation. *J. Clin. Invest.* **103**, 175–183 (1999). | [PubMed](#) | [ISI](#) | [ChemPort](#) |
9. Lafaille, J.J. *et al.* Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. *J. Exp. Med.* **186**, 307–312 (1997). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
10. Barthlott, T., Kassiotis, G. & Stockinger, B. T cell regulation as a side effect of homeostasis and competition. *J. Exp. Med.* **197**, 451–460 (2003). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
11. Bach, J.F. The effect of infections on susceptibility to autoimmune and allergic diseases. *N. Engl. J. Med.* **347**, 911–920 (2002). | [Article](#) | [PubMed](#) | [ISI](#) |
12. Wraith, D.C., Nicolson, K.S. & Whitley, N.T. Regulatory CD4(+) T cells and the control of autoimmune disease. *Curr. Opin. Immunol.* **16**, 695–701 (2004). | [Article](#) | [PubMed](#) | [ChemPort](#) |
13. Ling, E.M. *et al.* Relation of CD4⁺CD25⁺ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. *Lancet* **363**, 608–615 (2004). | [Article](#) | [PubMed](#) | [ChemPort](#) |
14. Cavani, A. *et al.* Human CD25⁺ regulatory T cells maintain immune tolerance to nickel in healthy, nonallergic individuals. *J. Immunol.* **171**, 5760–5768 (2003). | [PubMed](#) | [ISI](#) | [ChemPort](#) |
15. Karlsson, M.R., Rugtveit, J. & Brandtzaeg, P. Allergen-responsive CD4⁺CD25⁺ regulatory T cells in children who have outgrown cow's milk allergy. *J. Exp. Med.* **199**, 1679–1688 (2004). | [Article](#) | [PubMed](#) | [ChemPort](#) |

16. Ou, L.S., Goleva, E., Hall, C. & Leung, D.Y. T regulatory cells in atopic dermatitis and subversion of their activity by superantigens. *J. Allergy Clin. Immunol.* **113**, 756–763 (2004). | [Article](#) | [PubMed](#) | [ChemPort](#) |
17. Balandina, A., Lecart, S., Dartevielle, P., Saoudi, A. & Berrih-Aknin, S. Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. *Blood* **105**, 735–741 (2005). | [Article](#) | [PubMed](#) | [ChemPort](#) |
18. de Kleer, I.M. *et al.* CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. *J. Immunol.* **172**, 6435–6443 (2004). | [PubMed](#) | [ChemPort](#) |
19. Arif, S. *et al.* Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. *J. Clin. Invest.* **113**, 451–463 (2004). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
20. Viglietta, V., Baecher-Allan, C., Weiner, H.L. & Hafler, D.A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. *J. Exp. Med.* **199**, 971–979 (2004). | [Article](#) | [PubMed](#) | [ChemPort](#) |
21. Barrett, J.H., Brennan, P., Fiddler, M. & Silman, A.J. Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. *Arthritis Rheum.* **42**, 1219–1227 (1999). | [Article](#) | [PubMed](#) | [ChemPort](#) |
22. Platts-Mills, T., Vaughan, J., Squillace, S., Woodfolk, J. & Sporik, R. Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. *Lancet* **357**, 752–756 (2001). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
23. Durham, S.R. *et al.* Long-term clinical efficacy of grass-pollen immunotherapy. *N. Engl. J. Med.* **341**, 468–475 (1999). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
24. Bousquet, J. *et al.* Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. *Ann. Allergy Asthma Immunol.* **81**, 401–405 (1998). | [PubMed](#) | [ChemPort](#) |
25. Noon, L. Prophylactic inoculation against hay fever. *Lancet* **i**, 1572–1573 (1911). | [Article](#) |
26. Ebner, C. *et al.* Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. *Clin. Exp. Allergy* **27**, 1007–1015 (1997). | [PubMed](#) | [ISI](#) | [ChemPort](#) |
27. Secrist, H., Chelen, C.J., Wen, Y., Marshall, J.D. & Umetsu, D.T. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. *J. Exp. Med.* **178**, 2123–2130 (1993). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
28. Varney, V.A. *et al.* Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-

- induced late-phase cutaneous responses. *J. Clin. Invest.* **92**, 644–651 (1993). | [PubMed](#) | [ISI](#) | [ChemPort](#) |
29. Wachholz, P.A. *et al.* Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. *Immunology* **105**, 56–62 (2002). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
 30. Francis, J.N., Till, S.J. & Durham, S.R. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. *J. Allergy Clin. Immunol.* **111**, 1255–1261 (2003). | [ChemPort](#) |
 31. Jutel, M. *et al.* IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. *Eur. J. Immunol.* **33**, 1205–1214 (2003). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
 32. Nouri-Aria, K.T. *et al.* Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. *J. Immunol.* **172**, 3252–3259 (2004). | [PubMed](#) | [ChemPort](#) |
 33. Nasser, S.M., Ying, S., Meng, Q., Kay, A.B. & Ewan, P.W. Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. *Eur. J. Immunol.* **31**, 3704–3713 (2001). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
 34. Burkhart, C., Liu, G.Y., Anderton, S.M., Metzler, B. & Wraith, D.C. Peptide-induced T cell regulation of experimental autoimmune encephalomyelitis: a role for IL-10. *Int. Immunol.* **11**, 1625–1634 (1999). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
 35. Sundstedt, A., O'Neill, E. J., Nicolson, K. S. & Wraith, D. C. Role for IL-10 in suppression mediated by peptide-induced regulatory T cells *in vivo*. *J. Immunol.* **170**, 1240–1248 (2003). | [PubMed](#) | [ISI](#) | [ChemPort](#) |
 36. Barrat, F.J. *et al.* In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. *J. Exp. Med.* **195**, 603–616 (2002). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
 37. Mathisen, P.M., Yu, M., Johnson, J.M., Drazba, J.A. & Tuohy, V.K. Treatment of experimental autoimmune encephalomyelitis with genetically modified memory T cells. *J. Exp. Med.* **186**, 159–164 (1997). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
 38. Akdis, C.A. *et al.* Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 *in vitro*. *J. Clin. Invest.* **98**, 1676–1683 (1996). | [PubMed](#) | [ISI](#) | [ChemPort](#) |
 39. Akdis, C.A., Blesken, T., Akdis, M., Wuthrich, B. & Blaser, K. Role of interleukin 10 in specific immunotherapy. *J. Clin. Invest* **102**, 98–106 (1998). | [PubMed](#) | [ISI](#) | [ChemPort](#) |
 40. Jeannin, P., Lecoanet, S., Delneste, Y., Gauchat, J.F. & Bonnefoy, J.Y. IgE versus IgG4 production can be differentially regulated by IL-10. *J. Immunol.* **160**, 3555–3561 (1998). | [PubMed](#) | [ISI](#) | [ChemPort](#) |
 41. Galli, S.J., Nakae, S. & Tsai, M. Mast cells in the development of adaptive immune responses. *Nat. Immunol.* **6**, 135–142 (2005). | [Article](#) | [PubMed](#) | [ChemPort](#) |

42. Pedotti, R., De Voss, J.J., Steinman, L. & Galli, S.J. Involvement of both 'allergic' and 'autoimmune' mechanisms in EAE, MS and other autoimmune diseases. *Trends Immunol.* **24**, 479–484 (2003). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
43. Liblau, R.S., Singer, S.M. & McDevitt, H.O. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. *Immunol. Today* **16**, 34–38 (1995). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
44. Duda, P.W., Schmied, M.C., Cook, S.L., Krieger, J.I. & Hafler, D.A. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. *J. Clin. Invest.* **105**, 967–976 (2000). | [PubMed](#) | [ISI](#) | [ChemPort](#) |
45. Munari, L., Lovati, R. & Boiko, A. Therapy with glatiramer acetate for multiple sclerosis. *Cochrane Database Syst. Rev.* CD004678 (2004). | [PubMed](#) | [ChemPort](#) |
46. Johnson, K.P. *et al.* Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. *Mult. Scler.* **9**, 585–591 (2003). | [Article](#) | [PubMed](#) | [ChemPort](#) |
47. Johnson, K.P., Ford, C.C., Lisak, R.P. & Wolinsky, J.S. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. *Acta Neurol. Scand.* **111**, 42–47 (2005). | [Article](#) | [PubMed](#) | [ChemPort](#) |
48. Stern, J.N. *et al.* Amelioration of proteolipid protein 139-151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms. *Proc. Natl. Acad. Sci. USA* **101**, 11743–11748 (2004). | [Article](#) | [PubMed](#) | [ChemPort](#) |
49. Stern, J.N. *et al.* Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis. *Proc. Natl. Acad. Sci. USA* **102**, 1620–1625 (2005). | [Article](#) | [PubMed](#) | [ChemPort](#) |
50. Faria, A.M. & Weiner, H.L. Oral tolerance: mechanisms and therapeutic applications. *Adv. Immunol.* **73**, 153–264 (1999). | [PubMed](#) | [ISI](#) | [ChemPort](#) |
51. Dakin, R. Remarks on a cutaneous affection produced by certain poisonous vegetables. *Am. J. Med. Sci.* **4**, 98–100 (1829).
52. Weiner, H.L. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. *Immunol. Today* **18**, 335–343 (1997). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
53. Nussenblatt, R.B. *et al.* Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. *Am. J. Ophthalmol.* **123**, 583–592 (1997). | [PubMed](#) | [ISI](#) | [ChemPort](#) |
54. Sun, J.B., Rask, C., Olsson, T., Holmgren, J. & Czerkinsky, C. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. *Proc. Natl. Acad. Sci. USA* **93**, 7196–7201 (1996). | [Article](#) | [PubMed](#) | [ChemPort](#) |

55. Williams, N.A., Hirst, T.R., & Nashar, T.O. Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic. *Immunol. Today* **20**, 95–101 (1999). | [Article](#) | [PubMed](#) | [ChemPort](#) |
56. Chen, Y., Kuchroo, V.K., Inobe, J., Hafler, D.A., & Weiner, H.L. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. *Science* **265**, 1237–1240 (1994). | [PubMed](#) | [ISI](#) | [ChemPort](#) |
57. Maron, R., Melican, N.S., & Weiner, H.L. Regulatory Th2-type T cell lines against insulin and GAD peptides derived from orally- and nasally-treated NOD mice suppress diabetes. *J. Autoimmun.* **12**, 251–258 (1999). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
58. al Sabbagh, A., Nelson, P.A., Akselband, Y., Sobel, R.A., & Weiner, H.L. Antigen-driven peripheral immune tolerance: suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis by aerosol administration of myelin basic protein or type II collagen. *Cell. Immunol.* **171**, 111–119 (1996). | [Article](#) | [PubMed](#) | [ChemPort](#) |
59. Anderton, S.M., Burkhart, C., Liu, G.Y., Metzler, B. & Wraith, D. C. Antigen-specific tolerance induction and the immunotherapy of experimental autoimmune disease. *Novartis Found. Symp.* **215**, 120–131 (1998). | [PubMed](#) | [ChemPort](#) |
60. Alpan, O., Bachelder, E., Isil, E., Arnheiter, H. & Matzinger, P. 'Educated' dendritic cells act as messengers from memory to naive T helper cells. *Nat. Immunol* **5**, 615–622 (2004). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
61. Lehmann, P.V., Forsthuber, T., Miller, A. & Sercarz, E.E. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. *Nature* **358**, 155–157 (1992). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
62. Genain, C. P. *et al.* Late complications of immune deviation therapy in a nonhuman primate. *Science* **274**, 2054–2057 (1996). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
63. Blanas, E., Carbone, F.R., Allison, J., Miller, J.F. & Heath, W.R. Induction of autoimmune diabetes by oral administration of autoantigen. *Science* **274**, 1707–1709 (1996). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
64. Hanninen, A., Braakhuis, A., Heath, W. R., & Harrison, L. C. Mucosal antigen primes diabetogenic cytotoxic T-lymphocytes regardless of dose or delivery route. *Diabetes* **50**, 771–775 (2001). | [PubMed](#) | [ISI](#) | [ChemPort](#) |
65. Norman, P.S., Lichtenstein, L.M., & Marsh, D.G. Studies on allergoids from naturally occurring allergens. IV. Efficacy and safety of long-term allergoid treatment of ragweed hay fever. *J. Allergy Clin. Immunol.* **68**, 460–470 (1981). | [PubMed](#) | [ChemPort](#) |
66. Niederberger, V. *et al.* Vaccination with genetically engineered allergens prevents progression of allergic disease. *Proc. Natl. Acad. Sci. USA* **101** Suppl 2, 14677–14682 (2004). | [Article](#) | [PubMed](#) | [ChemPort](#) |

67. Valenta, R. *et al.* Genetically engineered and synthetic allergen derivatives: candidates for vaccination against type I allergy. *Biol. Chem.* **380**, 815–824 (1999). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
68. Hoyne, G.F., O'Hehir, R.E., Wraith, D.C., Thomas, W.R., & Lamb, J.R. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. *J. Exp. Med.* **178**, 1783–1788 (1993). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
69. Briner, T. J., Kuo, M. C., Keating, K. M., Rogers, B. L. & Greenstein, J. L. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. *Proc. Natl. Acad. Sci. USA* **90**, 7608–7612 (1993). | [PubMed](#) | [ChemPort](#) |
70. Norman, P.S. *et al.* Treatment of cat allergy with T-cell reactive peptides. *Am. J. Respir. Crit. Care Med.* **154**, 1623–1628 (1996). | [PubMed](#) | [ISI](#) | [ChemPort](#) |
71. Maguire, P., Nicodemus, C., Robinson, D., Aaronson, D. & Umetsu, D.T. The safety and efficacy of ALLERVAX CAT in cat allergic patients. *Clin. Immunol.* **93**, 222–231 (1999). | [Article](#) | [PubMed](#) | [ChemPort](#) |
72. Simons, F.E., Imada, M., Li, Y., Watson, W.T., & HayGlass, K.T. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. *Int. Immunol.* **8**, 1937–1945 (1996). | [PubMed](#) | [ISI](#) | [ChemPort](#) |
73. Pene, J. *et al.* Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. *J. Allergy Clin. Immunol.* **102**, 571–578 (1998). | [PubMed](#) | [ISI](#) | [ChemPort](#) |
74. Muller, U. *et al.* Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. *J. Allergy Clin. Immunol.* **101**, 747–754 (1998). | [PubMed](#) | [ISI](#) | [ChemPort](#) |
75. Fellrath, J.M. *et al.* Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. *J. Allergy Clin. Immunol.* **111**, 854–861 (2003). | [Article](#) | [PubMed](#) | [ChemPort](#) |
76. Oldfield, W.L., Kay, A.B. & Larche, M. Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. *J. Immunol.* **167**, 1734–1739 (2001). | [PubMed](#) | [ISI](#) | [ChemPort](#) |
77. Oldfield, W.L., Larche, M. & Kay, A.B. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. *Lancet* **360**, 47–53 (2002). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
78. Alexander, C., Tarzi, M., Larche, M. & Kay, A. B. The effect of Fel d 1-derived T cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. *Allergy*, in the press.
79. Alexander, C., Ying, S., Kay, B. & Larche, M. Fel d 1-derived T cell peptide therapy induces recruitment of CD4CD25⁺; CD4⁺ interferon-gamma T helper type 1 cells to sites of allergen-induced late-phase skin

- reactions in cat-allergic subjects. *Clin. Exp. Allergy* **35**, 52–58 (2005). | [Article](#) | [PubMed](#) | [ChemPort](#) |
80. Metzler, B. & Wraith, D.C. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. *Int. Immunol* **5**, 1159–1165 (1993). | [PubMed](#) | [ISI](#) | [ChemPort](#) |
81. Anderton, S.M. & Wraith, D.C. Hierarchy in the ability of T cell epitopes to induce peripheral tolerance to antigens from myelin. *Eur. J. Immunol* **28**, 1251–1261 (1998). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
82. Liu, J.Q. *et al.* Inhibition of experimental autoimmune encephalomyelitis in Lewis rats by nasal administration of encephalitogenic MBP peptides: synergistic effects of MBP 68-86 and 87-99. *Int. Immunol.* **10**, 1139–1148 (1998). | [Article](#) | [PubMed](#) | [ChemPort](#) |
83. Staines, N.A. *et al.* Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope. *Clin. Exp. Immunol.* **103**, 368–375 (1996). | [PubMed](#) | [ChemPort](#) |
84. Chu, C.Q. & Londei, M. Differential activities of immunogenic collagen type II peptides in the induction of nasal tolerance to collagen-induced arthritis. *J. Autoimmun.* **12**, 35–42 (1999). | [Article](#) | [PubMed](#) | [ChemPort](#) |
85. Prakken, B.J. *et al.* Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis. *Proc. Natl. Acad. Sci. USA* **94**, 3284–3289 (1997). | [Article](#) | [PubMed](#) | [ChemPort](#) |
86. Tian, J. *et al.* Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. *J. Exp. Med.* **183**, 1561–1567 (1996). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
87. Daniel, D. & Wegmann, D. R. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). *Proc. Natl. Acad. Sci. USA* **93**, 956–960 (1996). | [Article](#) | [PubMed](#) | [ChemPort](#) |
88. Elias, D. *et al.* Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta-cell antigens. *Diabetes* **46**, 758–764 (1997). | [PubMed](#) | [ChemPort](#) |
89. Thurau, S.R., Chan, C.C., Suh, E. & Nussenblatt, R.B. Induction of oral tolerance to S-antigen induced experimental autoimmune uveitis by a uveitogenic 20mer peptide. *J. Autoimmun.* **4**, 507–516 (1991). | [Article](#) | [PubMed](#) | [ChemPort](#) |
90. Karachunski, P.I., Ostlie, N.S., Okita, D.K. & Conti-Fine, B.M. Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences. *J. Clin. Invest* **100**, 3027–3035 (1997). | [PubMed](#) | [ChemPort](#) |

91. Paas-Rozner, M. *et al.* Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice. *Proc. Natl. Acad. Sci. USA* **97**, 2168–2173 (2000). | [Article](#) | [PubMed](#) | [ChemPort](#) |
92. Zou, L.P. *et al.* Antigen-specific immunosuppression: nasal tolerance to P0 protein peptides for the prevention and treatment of experimental autoimmune neuritis in Lewis rats. *J. Neuroimmunol.* **94**, 109–121 (1999). | [Article](#) | [PubMed](#) | [ChemPort](#) |
93. Raz, I. *et al.* Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. *Lancet* **358**, 1749–1753 (2001). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
94. Prakken, B.J. *et al.* Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. *Proc. Natl. Acad. Sci. USA* **101**, 4228–4233 (2004). | [Article](#) | [PubMed](#) | [ChemPort](#) |
95. Sloan-Lancaster, J. & Allen, P. M. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. *Annu.Rev.Immunol* **14**, 1–27 (1996). | [ChemPort](#) |
96. Franco, A. *et al.* T cell receptor antagonist peptides are highly effective inhibitors of experimental allergic encephalomyelitis. *Eur. J. Immunol.* **24**, 940–946 (1994). | [PubMed](#) | [ISI](#) | [ChemPort](#) |
97. Karin, N., Mitchell, D.J., Brocke, S., Ling, N. & Steinman, L. Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production. *J. Exp. Med.* **180**, 2227–2237 (1994). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
98. Kuchroo, V.K. *et al.* A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. *J. Immunol.* **153**, 3326–3336 (1994). | [PubMed](#) | [ISI](#) | [ChemPort](#) |
99. Nicholson, L.B., Murtaza, A., Hafler, B.P., Sette, A. & Kuchroo, V.K. A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens. *Proc. Natl. Acad. Sci. USA* **94**, 9279–9284 (1997). | [Article](#) | [PubMed](#) | [ChemPort](#) |
100. Kappos, L. *et al.* Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in relapsing MS Study Group. *Nat. Med.* **6**, 1176–1182 (2000). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
101. Bielekova, B. *et al.* Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. *Nat. Med.* **6**, 1167–1175 (2000). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |

102. Anderton, S.M., Manickasingham, S.P. & Wraith, D.C. Fine specificity of myelin basic protein reactive T-cells: implications for T-cell receptor antagonism. *Biochem. Soc. Trans.* **25**, 659–661 (1997). | [PubMed](#) | [ChemPort](#) |
103. Chai, J.G., James, E., Dewchand, H., Simpson, E. & Scott, D. Transplantation tolerance induced by intranasal administration of HY peptides. *Blood* **103**, 3951–3959 (2004). | [Article](#) | [PubMed](#) | [ChemPort](#) |
104. Kearney, E.R., Pape, K.A., Loh, D.Y. & Jenkins, M.K. Visualization of peptide-specific T cell immunity and peripheral tolerance induction *in vivo*. *Immunity* **1**, 327–339 (1994). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
105. Critchfield, J. M. *et al.* T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. *Science* **263**, 1139–1143 (1994). | [PubMed](#) | [ISI](#) | [ChemPort](#) |
106. Paas-Rozner, M., Sela, M., & Mozes, E. The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes. *Proc. Natl. Acad. Sci. USA* **98**, 12642–12647 (2001). | [Article](#) | [PubMed](#) | [ChemPort](#) |
107. Apostolou, I. & Von Boehmer, H. *In vivo* instruction of suppressor commitment in naive T cells. *J. Exp. Med.* **199**, 1401–1408 (2004). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
108. Verhoef, A., Alexander, C., Kay, A.B. & Larche, M. T Cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. *PLoS Med.*, in the press.
109. Haselden, B.M., Kay, A.B., & Larche, M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. *J. Exp. Med.* **189**, 1885–1894 (1999). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
110. Vidard, L., Colarusso, L.J., & Benacerraf, B. Specific T-cell tolerance may be preceded by a primary response. *Proc. Natl. Acad. Sci. USA* **91**, 5627–5631 (1994). | [PubMed](#) | [ChemPort](#) |
111. Webb, S., Morris, C. & Sprent, J. Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. *Cell* **63**, 1249–1256 (1990). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
112. Hoyne, G.F., Askonas, B.A., Hetzel, C., Thomas, W.R., & Lamb, J.R. Regulation of house dust mite responses by intranasally administered peptide: transient activation of CD4+ T cells precedes the development of tolerance *in vivo*. *Int. Immunol.* **8**, 335–342 (1996). | [PubMed](#) | [ChemPort](#) |
113. Ali, F.R., Oldfield, W.L., Higashi, N., Larche, M. & Kay, A. B. Late asthmatic reactions induced by inhalation of allergen-derived T cell peptides. *Am. J. Respir. Crit. Care Med.* **169**, 20–26 (2004). | [PubMed](#) |
114. Metzler, B., Anderton, S.M., Manickasingham, S.P., & Wraith, D.C. Kinetics of peptide uptake and tissue distribution following a single intranasal dose of peptide. *Immunol. Invest.* **29**, 61–70 (2000). | [PubMed](#) | [ISI](#) | [ChemPort](#) |

115. Arentz-Hansen, H. *et al.* The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. *J. Exp. Med.* **191**, 603–612 (2000). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
116. Martin, R., McFarland, H.F. & McFarlin, D.E. Immunological aspects of demyelinating diseases. *Annu. Rev. Immunol* **10**, 153–187 (1992). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
117. Southwood, S. *et al.* Several common HLA-DR types share largely overlapping peptide binding repertoires. *J. Immunol.* **160**, 3363–3373 (1998). | [PubMed](#) | [ChemPort](#) |
118. Texier, C. *et al.* HLA-DR restricted peptide candidates for bee venom immunotherapy. *J. Immunol.* **164**, 3177–3184 (2000). | [PubMed](#) | [ChemPort](#) |
119. Anderton, S.M., Viner, N.J., Matharu, P., Lowrey, P.A. & Wraith, D.C. Influence of a dominant cryptic epitope on autoimmune T cell tolerance. *Nat. Immunol* **3**, 175–181 (2002). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
120. Shen, C.R. *et al.* Peptides containing a dominant T-cell epitope from red cell band 3 have in vivo immunomodulatory properties in NZB mice with autoimmune hemolytic anemia. *Blood* **102**, 3800–3806 (2003). | [Article](#) | [PubMed](#) | [ChemPort](#) |
121. Santambrogio, L., Sato, A.K., Fischer, F.R., Dorf, M.E. & Stern, L.J. Abundant empty class II MHC molecules on the surface of immature dendritic cells. *Proc. Natl. Acad. Sci. USA* **96**, 15050–15055 (1999). | [Article](#) | [PubMed](#) | [ChemPort](#) |
122. Jonuleit, H., Schmitt, E., Schuler, G., Knop, J. & Enk, A. H. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. *J. Exp. Med.* **192**, 1213–1222 (2000). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
123. Wakkach, A. *et al.* Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. *Immunity* **18**, 605–617 (2003). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
124. Dhodapkar, M.V., Steinman, R.M., Krasovsky, J., Munz, C. & Bhardwaj, N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. *J. Exp. Med.* **193**, 233–238 (2001). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
125. Menges, M. *et al.* Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. *J. Exp. Med.* **195**, 15–21 (2002). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
126. Zamvil, S.S. *et al.* T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. *Nature* **324**, 258–260 (1986). | [Article](#) | [PubMed](#) | [ISI](#) | [ChemPort](#) |
127. Liu, G.Y. & Wraith, D.C. Affinity for class II MHC determines the extent to which soluble peptides tolerize autoreactive T cells in naive and primed adult mice—implications for autoimmunity. *Int. Immunol.* **7**, 1255–1263 (1995). | [PubMed](#) | [ISI](#) | [ChemPort](#) |

Metzler, B. & Wraith, D.C. Inhibition of T-cell responsiveness by nasal peptide administration: influence of the thymus and differential recovery of T-cell-dependent functions. *Immunology* **97**, 257–263 (1999). | [Article](#) | [PubMed](#)